News

Biotech

The small molecule with a big future

Researchers identify small molecule that restores visual function after optic nerve injury

Telocyte’s gene therapy funded through to clinical trials

Michael Fossel on securing new investment, taking telomerase gene therapy to the clinic, and its potential in cardiovascular disease.

Hypertension drug rilmenidine can extend lifespan and slow aging

Humacyte publishes 6-year outcomes in Phase 2 study of its Human Acellular Vessel

HRT could ward off Alzheimer’s disease in at-risk women

Rapamycin – the most promising life extension drug?

Making a noise about the silent killer

AmyriAD’s Alzheimer’s drug ready for Phase 3 trials

Cyclarity’s guardians are leading the battle against atherosclerosis

Alzheimer’s drug lecanemab granted Accelerated Approval from FDA

Longevity biotech: ‘This is still just the beginning’

Biosplice announces data from osteoarthritis clinical trial – and the initiation of new phase 3 trial

Harnessing the potential of regenerative stem cell secretomes in age-related disease

Innovative atherosclerosis treatment readies for clinical trials

Kristen Fortney on the pathway to longevity

Innovative cancer treatment device has longevity potential

Antiaging drug rapamycin might only benefit females, new research shows

Genflow builds on SIRT6 research with new patent

Cellular ‘glue’ can regenerate tissues, heal wounds and regrow nerves

Rise of the WormBots: it’s time to scale up longevity R&D

Tick, tock… funding calls for both aging clocks and psychedelics and longevity grant proposals

Do mitochondria hold the key to a Parkinson’s breakthrough?

Time to Turn the other cheek

BioAge announces positive topline results for clinical trial evaluating muscle atrophy

Cajal Neuroscience launches with $96 million to transform neurodegeneration drug discovery

Eisai-Biogen Alzheimer’s drug slows cognitive decline – but safety concerns persist

Is aging a question of order vs disorder?

Clinical trial death raises safety concerns about promising Alzheimer’s therapy

New small molecule drug for lowering cholesterol

Constructively disruptive – tackling atherosclerosis through disease reversal

Juvena Therapeutics bags $41 million to accelerate biologics for age-related diseases

Find us here ...

© Copyright 2022 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

First Longevity Ltd is an appointed representative of Prospect Capital Ltd which is authorised and regulated by the Financial Conduct Authority.
The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.